What Celestine Treats: Main Uses and Benefits

Celestine is commonly used for long-term fertility control. Its uses extend to the therapeutic management of several conditions where patients experience heightened symptoms. The medication is relevant for easing groups of symptoms that may become disruptive, including severe menstrual pain (dysmenorrhea), excessive menstrual blood loss (menorrhagia), and moderate hormonal acne vulgaris.

The benefit in these scenarios is focused on symptom stabilization, where it assists with maintaining functional stability during symptomatic periods. This dual-purpose utility is why it is often chosen:

The treatment helps manage symptoms related to both family planning and monthly distress.

Beyond immediate symptom relief, long-term use may assist with the reduction of risk for developing ovarian and endometrial cancers. This provides support that contributes to easing the overall symptom load.

---

Quick Fact: Relief for Menstrual Distress

Celestine is applied in clinical settings for the symptomatic relief of painful periods and heavy bleeding, supporting patients in coping more steadily with symptom fluctuations.

Regulatory References

1. NIH MedlinePlus Drug Information

Celestine is officially indicated for use by women of reproductive potential to prevent pregnancy, including postpubertal adolescents. However, regulatory agencies establish clear exclusions based on underlying health status and age.

The medicine is absolutely contraindicated for use in several populations due to increased cardiovascular risk and hormone sensitivity. Use is strictly prohibited for:

• Women over 35 years of age who smoke.
• Those with known or suspected pregnancy.
• A history of thromboembolic disorders (e.g., DVT, stroke, MI) or known thrombophilic conditions.
• Migraine with focal neurological symptoms (aura).
• Active severe liver disease, liver tumors, or breast cancer/estrogen-dependent neoplasia.
• Diabetes with vascular involvement, or severe uncontrolled hypertension.

Use is not recommended for women who are breastfeeding, as it may decrease milk production. The medicine is not indicated for use in the geriatric population, and it should not be initiated before the start of menstruation. Discontinuation is also required prior to and immediately following major surgery or periods of prolonged immobilization due to increased thromboembolism risk.

Interactions with other medicines and products

Celestine (Desogestrel/Ethinylestradiol) has officially documented interaction patterns structured around metabolic pathways and heightened thrombotic risk, as specified in regulatory labels.

Prohibited Combinations and Restrictions

Co-administration is contraindicated with specific Hepatitis C virus medicinal products, including combinations of ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This prohibition is due to the documented potential for elevated liver enzymes. Oral tranexamic acid is also prohibited due to official pharmacodynamic concerns regarding increased thrombotic risk. A population restriction formally contraindicates the use of this product in women over 35 years of age who smoke.

Metabolic and Exposure Alterations

The efficacy of Celestine may be reduced by concurrent use with substances that induce hepatic enzymes, such as the anticonvulsants Rifampin and Phenytoin, or the herbal product St. John's wort. This results in the documented outcome of decreased exposure to the hormonal components. Additionally, certain antibiotics are noted to alter intestinal flora, which can affect the absorption pathway. Conversely, the estrogen component can inhibit the clearance of co-administered drugs like caffeine and certain benzodiazepines, leading to increased plasma concentrations of those agents.

Mandatory Timing Rules

The regulatory label requires the product to be discontinued for at least four weeks prior to and for two weeks following any major surgery or prolonged immobilization. This is a mandatory procedural constraint related to the heightened risk of thromboembolism during those periods.

The mechanism of Celestine is a coordinated, multi-level biological process involving two synthetic hormones, Desogestrel and Ethinylestradiol, which act as agonists at the Progesterone and Estrogen Receptors, respectively. This dual action creates a multi-layered physiological state that functionally inhibits conception. The total mechanism is executed across three primary, complementary domains.

---

Central Suppression of the Ovulatory Cycle (Anovulation)

The synthetic hormones exert negative feedback on the Hypothalamic-Pituitary-Ovarian (HPO) axis . This central action functionally blocks the release of Follicle-Stimulating Hormone ( FSH) and the critical Luteinizing Hormone ( LH) surge, arresting the development of ovarian follicles and resulting in anovulation (the failure to release an egg from the ovary).

---

Peripheral Barrier Mechanisms

The active progestogen component acts directly on the reproductive tract tissues, providing secondary mechanisms. It causes the cervical mucus to become markedly thick, viscous, and less permeable, forming a physical barrier that restricts sperm mobility. Concurrently, it causes the endometrial lining to remain thin and atrophic, rendering the uterine environment unreceptive to a fertilized ovum.

---

Mechanistic Redundancy and Synergy

The combination of estrogen and progestogen ensures the presence of multiple layers of pathway modulation. The estrogen component enhances the central suppression of FSH, while the progestogen drives both the primary LH surge blockade and the crucial peripheral barrier effects. This synergy supports the action across multiple physiological systems, leveraging multiple physiological changes to establish the necessary protective state.

Celestine is administered via the oral route as a fixed-dose tablet, following a continuous cyclic use pattern. The standard schedule is based on a 28-day regimen, which directs the user to take one tablet once daily at the same time each day. This schedule typically comprises 21 consecutive days of the active (hormonal) tablets, followed by seven consecutive days of inactive (placebo) tablets, or no pill.

To initiate treatment, a patient may use a Day 1 Start (on the first day of menstruation) or a Sunday Start. If the tablet is started after the first day of the menstrual period, an additional non-hormonal back-up method must be used for the initial seven consecutive days to ensure the proper onset of the regimen’s effect. This daily dose is approved for use in adults and postpubertal adolescents.

For proper administration, the tablet can be consumed with or without liquid; however, product instructions advise against the consumption of grapefruit or grapefruit juice due to potential impacts on absorption. Consistency in timing is a critical procedural requirement. Should a single active tablet be missed, the instruction is to take the missed dose immediately, while specific, detailed protocols must be followed if multiple doses are missed, as outlined in the product labeling.

Research Evidence / Overview of Studies for Celestine

This section provides an objective overview of the scientific research that has explored the use of Celestine (Desogestrel/Ethinylestradiol). It describes the types of studies conducted and what was measured, but it does not offer any clinical advice or individual recommendations. Findings describe group patterns, not personal outcomes; research does not determine whether an individual will respond similarly.

---

Evidence for the Primary Use: Pregnancy Prevention (Contraception)

These studies primarily focused on healthy women of reproductive age and monitored the contraceptive pregnancy rate (Pearl Index). The evidence for this use is classified as High-level by major guideline bodies. Regulatory trials reported measurements of pregnancy rates under conditions of "perfect use" in research settings.

However, the outcome rates observed in everyday use are influenced by factors related to user adherence and consistent product intake. Comparative evidence is lacking for this specific combination against every other individual hormonal product in long-term head-to-head trials.

Evidence for Symptom Management

Research on Severe Menstrual Pain (Dysmenorrhea) and Heavy Bleeding (Menorrhagia)

Research has explored the use of combined hormonal contraceptives (CHCs) for conditions involving periods of heightened symptoms. Studies examined outcomes related to physical discomfort (pain scales) and outcomes reflecting daily functioning or activity level. Findings describe patterns observed in the studies related to changes in the intensity of pain and in the requirement for supportive medication. The evidence for exploring these symptoms relies heavily on the overall research base established for CHCs as a general class, and follow-up durations were limited for many of these trials.

Research on Moderate Hormonal Acne Vulgaris

Research examined the use of combined hormonal pills in post-menarchal women and adolescents with mild to moderate acne. Studies monitored changes in facial lesion counts and assessed changes using clinician-graded severity scales. Findings describe patterns observed in the studies where changes in lesion counts were measured in the group studied, generally after a minimum of three to six months of continuous treatment.

Long-Term Evidence and Associated Health Outcomes

Very long-term research is primarily derived from large-scale epidemiological studies that track women over decades. This research monitored the incidence rates of ovarian cancer and endometrial cancer in women who have ever used COCs. Large-scale observational data describe patterns related to incidence of these two cancer types in the study populations. Because this evidence is primarily observational, it documents associations and does not establish a definitive cause-and-effect relationship.

Key Studies & References U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 - Centers for Disease Control and Prevention (CDC)

Common questions about Celestine (FAQ)

Q: How quickly should I expect to feel the effects of Celestine?

A: Official instructions indicate that the start of contraceptive action is either immediate or after seven consecutive days of active tablet use, depending on the day the pack is started. Regarding non-intended effects, common minor adverse reactions, such as nausea, are documented to be more frequent during the first two weeks of treatment.

Q: What is the average time it takes for Celestine to start working?

A: If Celestine is started on the first day of the menstrual period, regulatory guidelines indicate that contraceptive action begins immediately. If started on a different day, regulatory guidelines note that a non-hormonal back-up method is advised for the initial seven consecutive days to help establish the regimen's effect.

Q: Does Celestine have a lot of drug interactions to watch out for?

A: Regulatory documents list specific prohibited combinations, such as certain Hepatitis C medications, due to the potential for elevated liver enzymes. The label also specifies interactions where certain other medications are documented to either decrease the documented efficacy of Celestine or increase the plasma concentrations of co-administered agents.

Q: Is it okay to drink coffee while taking Celestine?

A: The estrogen component in Celestine is documented to potentially inhibit the body's clearance of caffeine. This effect could result in increased concentrations of caffeine in the bloodstream.

Q: Does Celestine affect sleep patterns?

A: Official reports indicate that insomnia (difficulty sleeping) is listed as a common adverse reaction associated with the use of Celestine.

Q: Is it normal to feel [minor symptom, e.g., slightly nauseous] when first starting Celestine?

A: Nausea is classified as a very common adverse reaction in the official safety profile. This symptom is specifically documented to occur more frequently during the initial two weeks of treatment.

Q: Are there any known issues combining Celestine with herbal supplements?

A: The efficacy of Celestine may be reduced by concurrent use with the herbal product St. John's wort. This is because St. John's wort is an enzyme inducer, a known interaction that can lead to decreased exposure to the hormonal components of Celestine.

Q: Does Celestine cause weight gain or loss?

A: Weight gain is listed as a common adverse reaction in clinical trial data for combined hormonal contraceptives.

Q: What happens if you miss a dose of Celestine?

A: Regulatory labeling addresses single-dose misses by directing the user to take the missed dose immediately. Specific, detailed protocols for managing multiple missed doses are outlined in the patient information leaflet.

Q: Is Celestine safe for older adults or seniors?

A: Official labeling states that Celestine is not indicated for use in the geriatric population. Furthermore, its use is strictly contraindicated in women over 35 years of age who smoke due to heightened cardiovascular risk.

Q: What are the typical lifestyle changes recommended while on Celestine?

A: Official instructions include avoiding the consumption of grapefruit or grapefruit juice due to potential impacts on absorption. Additionally, use is contraindicated in women over 35 years of age who smoke.

Q: How long does Celestine stay in your system after stopping it?

A: The body eliminates the active ingredients over a relatively short period. The risk of thromboembolic disease associated with combined oral contraceptives is documented to gradually diminish after the product is discontinued.

Q: Are there any specific dietary restrictions when taking Celestine?

A: Official instructions advise against the consumption of grapefruit or grapefruit juice because of its potential to impact the absorption of the medicine.

Q: What kind of research has been done on the long-term effectiveness of Celestine?

A: Research has focused on measuring contraceptive pregnancy rates (Pearl Index) in reproductive-aged women. Very long-term evidence on associated health outcomes, such as cancer incidence rates, is primarily derived from large-scale observational (epidemiological) studies that track women over decades.

Q: Does Celestine affect fertility or reproductive health?

A: Celestine is indicated to prevent pregnancy. Official documentation notes that after discontinuing the product, some women may experience post-pill amenorrhea (absence of a period) or oligomenorrhea (infrequent periods), particularly if these were pre-existing conditions.

Q: Is Celestine known to cause problems with liver or kidney function?

A: Regulatory warnings state that patients with active severe liver disease or liver tumors must not use this product. For kidney function, patients with renal impairment require monitoring and potential dose adjustments due to documented changes in drug exposure.

Q: Can Celestine be taken by people with pre-existing heart conditions?

A: Use of Celestine is strictly prohibited for individuals with a history of thromboembolic disorders (such as stroke or myocardial infarction), or severe uncontrolled high blood pressure (hypertension).

Q: Does the efficacy of Celestine decrease over time?

A: Clinical trials measure high effectiveness rates with consistent use. The regulatory label notes that the risk of thromboembolic disease associated with its use is documented to be highest during the first year of treatment.

Q: What happens if Celestine is taken with alcohol?

A: The label notes that using alcohol with certain medicines may cause interactions. Information on co-administration with alcohol is available in the full product labeling.

Q: Does Celestine require regular blood tests or monitoring?

A: Official restrictions mandate periodic monitoring of liver function tests (LFTs) due to the documented risk of Hepatobiliary Disorders.

Q: Is Celestine used for any conditions other than its primary indication?

A: Celestine is officially indicated solely for the prevention of pregnancy. The research evidence section does, however, explore the outcomes related to symptom management for severe menstrual pain, heavy bleeding, and moderate hormonal acne vulgaris.

Q: Can Celestine cause changes in mood or personality?

A: Changes in mood, including depression and depressed mood, are listed as adverse reactions in official labeling. The label notes that women with a history of depression should be monitored carefully while using this product.

Q: Is there a link between Celestine and headaches or migraines?

A: Headache is classified as a very common adverse reaction. Migraine with focal neurological symptoms (aura) is a contraindication for use. The regulatory label notes that the onset or worsening of migraines or the development of a new pattern of severe headache requires discontinuation of the oral contraceptive.

Q: Does Celestine interfere with common lab test results?

A: Yes, regulatory documents state that the use of hormonal contraceptives may influence the results of certain laboratory tests. These include tests for liver, thyroid, and adrenal function, as well as binding proteins and coagulation parameters.

Q: Are there different strengths or dosages of Celestine available?

A: Celestine is provided as a fixed-dose combination product in the active tablets. This means each active tablet contains the same predetermined amounts of Desogestrel and Ethinylestradiol.

Q: Do I need a special prescription or monitoring for Celestine?

A: Celestine is classified as a prescription-only medicine. The label also requires periodic monitoring of liver function tests due to the documented risk of Hepatobiliary Disorders.

Q: What is the role of Celestine in a broader treatment plan?

A: The primary role of Celestine is for the reliable prevention of pregnancy. For other symptoms, research on combined hormonal contraceptives suggests a role in managing conditions such as severe menstrual pain and moderate hormonal acne vulgaris.

Q: Can taking Celestine make you more sensitive to the sun?

A: Official warnings note that chloasma (dark patches of skin) may occur, particularly in those who have had it during pregnancy. Females with a history of chloasma are advised to avoid exposure to the sun or ultraviolet radiation while using this product.

How to Store and Dispose of Celestine (Official Regulatory Information)

Requirement	Official Statement (Based on Regulatory Labeling)
Storage Conditions	Store the product in a cool, dry, and well-ventilated place, maintaining a recommended temperature range of 15 C to 25 C (Room Temperature).
Protection Rules	Keep the container tightly closed to protect the material. Storage must avoid incompatible materials such as strong oxidizing agents and must be kept away from heat and sources of ignition.
Stability	The material is classified as chemically stable when kept under the recommended storage and handling conditions.
Disposal Rules	Disposal of all surplus material and contaminated packaging must be carried out by a licensed disposal company in accordance with all current local and national waste legislation.
Environmental Caution	Do not discharge the material into sewers, drains, or waterways to prevent environmental release.

Connection to the official storage/disposal profile: Regulatory labeling requires strict environmental controls for storage, mandating that the product is kept cool, dry, and sealed to maintain its chemical stability. Disposal is defined as a regulated waste process that prohibits environmental contamination and necessitates the use of licensed waste facilities, ensuring compliance with governmental waste management laws.